Linsitinib (OSI-906)

For research use only.

Catalog No.S1091

114 publications

Linsitinib (OSI-906) Chemical Structure

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 186 In stock
EUR 167 In stock
EUR 265 In stock
EUR 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Linsitinib (OSI-906) has been cited by 114 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEK4NFYh|ryP MX;TRW5ITVJ?
KS-1 NEj3e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHDfoxRUUN3ME2wMlA{QDN3IN88US=> NF;3cW1USU6JRWK=
TE-11 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD1yLkC3PFIzKM7:TR?= NHjwUm1USU6JRWK=
EW-1 NF;SVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEi1PFUh|ryP MWDTRW5ITVJ?
HMV-II MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnniTWM2OD1yLkC4PFQ3KM7:TR?= NY\a[lRjW0GQR1XS
COLO-205 NEHVUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUC0OVQh|ryP NVHZW5p7W0GQR1XS
ES1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnOVWh{UUN3ME2wMlExPjl4IN88US=> M17rRXNCVkeHUh?=
GDM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMUO2O|Ih|ryP M{KxT3NCVkeHUh?=
ML-2 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz1foRKSzVyPUCuNVU5QTZizszN NUC0d2p1W0GQR1XS
Saos-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7pcGZKSzVyPUCuNVY2OjZizszN NV3wNHB2W0GQR1XS
NCI-H1355 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJfmRNUUN3ME2wMlE5OTN3IN88US=> NWn3WldDW0GQR1XS
G-401 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn36TWM2OD1yLkG4NlMh|ryP NGDy[I9USU6JRWK=
EW-16 NYPYcY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jTXmlEPTB;MD6xPFc4PyEQvF2= NGSwOIZUSU6JRWK=
EW-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf2TWM2OD1yLkG4PFgyKM7:TR?= MYTTRW5ITVJ?
NCI-H727 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMUm3PVQh|ryP NX3wWldsW0GQR1XS
LCLC-97TM1 NYjvb4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\EVndJUUN3ME2wMlIxQTV3IN88US=> NIfZZ|NUSU6JRWK=
NCI-H650 NF2zTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwdlJCUUN3ME2wMlIyOzh2IN88US=> NFzvZllUSU6JRWK=
NCI-H2122 NXvWWm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0TWM2OD1yLkKzNlk6KM7:TR?= NF:4NW9USU6JRWK=
SK-N-DZ NGHmVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DodmlEPTB;MD6yN|Y6QCEQvF2= MV3TRW5ITVJ?
HT-29 NEjmRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LVNmlEPTB;MD6yOFI1QCEQvF2= M2jqbnNCVkeHUh?=
LB771-HNC M2PzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnlVY1KSzVyPUCuNlU6OTVizszN NIjNUI9USU6JRWK=
HT-144 NUnWPGpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:4VmZKSzVyPUCuNlYyQTFizszN M{PBdXNCVkeHUh?=
LAN-6 NFXXd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMk[zOFgh|ryP M3\sWXNCVkeHUh?=
EW-18 NGnvU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPdnpKSzVyPUCuNlcxODFizszN NHnuO2pUSU6JRWK=
LS-1034 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LJN2lEPTB;MD6yO|E{OiEQvF2= NYHuXXdTW0GQR1XS
EW-11 NXrod29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHNbmlKSzVyPUCuNlg1OzJizszN MUHTRW5ITVJ?
SNU-C1 NFWwemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0OGlEPTB;MD6yPVMyOyEQvF2= Mlv5V2FPT0WU
RS4-11 NXvBeFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HqTmlEPTB;MD6zN|c2QCEQvF2= NHSzRmdUSU6JRWK=
ES4 NGHVNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPlOXRGUUN3ME2wMlQyODN6IN88US=> NFPyN3pUSU6JRWK=
COLO-320-HSR NYXhbFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli3TWM2OD1yLkSxN|Y5KM7:TR?= M3z1c3NCVkeHUh?=
NB10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuyVodKSzVyPUCuOFU1OzdizszN NWfLOZl5W0GQR1XS
BFTC-905 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNE[3OVgh|ryP M3LTbnNCVkeHUh?=
A375 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm0dWwyUUN3ME2wMlQ4PjF5IN88US=> MXjTRW5ITVJ?
SJRH30 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPmTWM2OD1yLkWwPFIzKM7:TR?= M2\1ZXNCVkeHUh?=
NOS-1 NWniSId[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnztTWM2OD1yLkWyNlY4KM7:TR?= NGXj[2tUSU6JRWK=
SIG-M5 M4rxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7m[WdyUUN3ME2wMlU{PTV5IN88US=> M{To[XNCVkeHUh?=
DOK NUP0Z4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIPIt1UUN3ME2wMlU2PiEQvF2= M3m2WXNCVkeHUh?=
NB69 NFz3[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwNUiyOVch|ryP NWe3U|V7W0GQR1XS
SK-NEP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXSTWM2OD1yLk[wNlM3KM7:TR?= MoX5V2FPT0WU
SK-MM-2 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNkW0PVEh|ryP MYrTRW5ITVJ?
NCI-H358 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLlTWM2OD1yLk[3NFgzKM7:TR?= M3LMXnNCVkeHUh?=
RH-1 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILpU45KSzVyPUCuO|Q5PTlizszN MWjTRW5ITVJ?
NH-12 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwN{[wOFYh|ryP M2rUXnNCVkeHUh?=
TE-12 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1yLke2OFg3KM7:TR?= Mon6V2FPT0WU
COLO-668 M1f5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe4W2FKSzVyPUCuPFQ3PjZizszN MnzWV2FPT0WU
PANC-08-13 NEn2VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmToTWM2OD1yLki2N|c4KM7:TR?= M3KyOnNCVkeHUh?=
HCC2998 NWH2RlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjzS3Y1UUN3ME2wMlg5OjZ|IN88US=> MlnUV2FPT0WU
ABC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfUZmRSUUN3ME2wMlkxOzV{IN88US=> M{DYPHNCVkeHUh?=
ES6 NIrCT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;VeZV1UUN3ME2wMlkyODZ4IN88US=> Ml;IV2FPT0WU
SNU-387 NUfm[pdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;UTWM2OD1yLkm5N|k{KM7:TR?= NVi4dHF5W0GQR1XS
CMK NIfJ[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwOUm5Nlkh|ryP NWDaZVhrW0GQR1XS
SJSA-1 M1PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TsN2lEPTB;MT6wN|Y2OyEQvF2= NW\EWFUxW0GQR1XS
SIMA MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GwOGlEPTB;MT6wOlgzPSEQvF2= M{e5[3NCVkeHUh?=
ES3 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMUKyPVch|ryP MnHrV2FPT0WU
IGROV-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwMUW0OFQh|ryP NGnIN2VUSU6JRWK=
MEL-JUSO NVu3eoduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjDTWM2OD1zLkG1O|U6KM7:TR?= NY\reVdjW0GQR1XS
T84 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Kc2lEPTB;MT6yNFkyPCEQvF2= M33CT3NCVkeHUh?=
CAL-85-1 NFfrbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF73S3ZKSzVyPUGuNlMyOzhizszN MU\TRW5ITVJ?
RD M{LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\CTWM2OD1zLkK2OFU2KM7:TR?= NWW3OJdCW0GQR1XS
TE-8 M{n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwM{G0OlIh|ryP MUjTRW5ITVJ?
L-363 NVT2NppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnmZXpKSzVyPUGuN|QzODhizszN NGm4clZUSU6JRWK=
EKVX MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS0TWM2OD1zLkO0OVY5KM7:TR?= NUTlb5JyW0GQR1XS
SK-MEL-3 M2TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX71WHM5UUN3ME2xMlQ5PTV4IN88US=> NFjBNIZUSU6JRWK=
TGBC24TKB M{XqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwNUCxPVMh|ryP NF\TZYpUSU6JRWK=
NCI-H1770 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65eoRKSzVyPUGuOVEyOTNizszN NXjaWXR[W0GQR1XS
HuH-7 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\sTWM2OD1zLk[wNFk5KM7:TR?= MkfvV2FPT0WU
HL-60 NG\ZbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYNnV5UUN3ME2xMlY3QTJ6IN88US=> MXnTRW5ITVJ?
TE-1 NWDTXJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:2RmlEPTB;MT63NFk1PSEQvF2= MXHTRW5ITVJ?
LC-2-ad M{DkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjtTWM2OD1zLkezPFg4KM7:TR?= NUXZUFZIW0GQR1XS
LB647-SCLC M332UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwN{[1PFMh|ryP MlPqV2FPT0WU
NCI-H2171 M{nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV24Smo{UUN3ME2xMlc4PzF4IN88US=> MYPTRW5ITVJ?
SK-PN-DW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPlXJhKSzVyPUGuPVEzQThizszN M2TidXNCVkeHUh?=
MC-IXC M1u5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P4fWlEPTB;MT65PFk5KM7:TR?= MmrmV2FPT0WU
LS-513 NXn0cXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTOdVZVUUN3ME2yMlA2OzB3IN88US=> MonSV2FPT0WU
EW-3 NWDwTG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwMEm4OFQh|ryP NHLFTY1USU6JRWK=
OPM-2 NGn3NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwMUCyJO69VQ>? NGXJNmFUSU6JRWK=
LP-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwMkW4NFch|ryP M2\FZ3NCVkeHUh?=
LU-134-A Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwMke3JO69VQ>? MmH1V2FPT0WU
CP66-MEL Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMkmwNVQh|ryP NVuwempyW0GQR1XS
HCC1143 M3r2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwNEWzOlgh|ryP Mmr1V2FPT0WU
LOXIMVI MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfQOpNKSzVyPUKuOlAzOSEQvF2= MUTTRW5ITVJ?
TE-10 NX65PI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXv[mt3UUN3ME2yMlcxQDN6IN88US=> MXTTRW5ITVJ?
NCI-H1882 NXfjWoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\LPYRYUUN3ME2yMlc2OjJ5IN88US=> MnvmV2FPT0WU
CHP-126 NEjJZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPpZXpvUUN3ME2yMlc3OzF5IN88US=> NXXBO3l4W0GQR1XS
NCI-H1623 NYrNU5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTITnRqUUN3ME2yMlkzODJ2IN88US=> M{DYS3NCVkeHUh?=
GB-1 M2jVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XKZWlEPTB;Mj65N|QxPCEQvF2= NXnIcW1sW0GQR1XS
RCC10RGB M3TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPYWlBsUUN3ME2yMlk2OjhzIN88US=> MkDVV2FPT0WU
NCI-H2141 M1vFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vTe2lEPTB;Mj65Olg6PiEQvF2= MkXNV2FPT0WU
GI-ME-N NUH1NY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWzTWM2OD1|LkCwOVY2KM7:TR?= MoTtV2FPT0WU
NCI-H526 NGfIVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfLPZVKSzVyPUOuNFQxQDVizszN M4O5SHNCVkeHUh?=
NCI-H747 NWGx[YhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwMES5PVIh|ryP Ml;QV2FPT0WU
SNU-423 NY\yPWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnzPFR3UUN3ME2zMlIxOzF|IN88US=> MkfkV2FPT0WU
A427 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzzeHJKSzVyPUOuNlU3QTlizszN MX\TRW5ITVJ?
CAL-12T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LlOGlEPTB;Mz60NFcyOyEQvF2= NVHrbYxIW0GQR1XS
LU-99A NVu2PIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLh[JRxUUN3ME2zMlQ4OTB3IN88US=> NFiwXYxUSU6JRWK=
MS-1 M4jBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPNTWM2OD1|LkWzOFI6KM7:TR?= MmDaV2FPT0WU
SK-LU-1 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XGOmlEPTB;Mz63OlI6PSEQvF2= NWn5UlA3W0GQR1XS
SW837 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwN{[zN|Mh|ryP MnPvV2FPT0WU
ES8 NIHh[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:4fmlEPTB;Mz64N|g4PyEQvF2= NUTHfWdrW0GQR1XS
MZ2-MEL NYDrfVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvS[2FHUUN3ME2zMlkzODh4IN88US=> MU\TRW5ITVJ?
TGW NE\kNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSxUINKSzVyPUSuNFE{OTFizszN NYn1XZhQW0GQR1XS
GP5d MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHP[FRLUUN3ME20MlA2OzZ{IN88US=> M2\QUXNCVkeHUh?=
BB49-HNC MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7sN|BKSzVyPUSuNVUzOTNizszN NHLUd|ZUSU6JRWK=
NB13 M3m0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHITWM2OD12LkK2PFg4KM7:TR?= NVXKfo12W0GQR1XS
NTERA-S-cl-D1 M{XTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XyNmlEPTB;ND6yPFYyPSEQvF2= MX7TRW5ITVJ?
NCI-H1648 M4n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMVJdSUUN3ME20MlI6QDF7IN88US=> NIf5NVRUSU6JRWK=
LCLC-103H M3nhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y4NWlEPTB;ND6zNlE6PSEQvF2= NH7X[mJUSU6JRWK=
LS-411N NH3JXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDWUo9KSzVyPUSuOFQ5QDVizszN MUPTRW5ITVJ?
NCI-H1092 NWHMRXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwNEW2PFch|ryP MljmV2FPT0WU
PANC-10-05 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XTemlEPTB;ND62PVg1KM7:TR?= Mn3lV2FPT0WU
DK-MG NVrmeZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv0coxvUUN3ME20MlgxQTN|IN88US=> NUXXbVlNW0GQR1XS
OVCAR-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX64TGxrUUN3ME20MlgyOjJ4IN88US=> Mmj2V2FPT0WU
CAL-39 NF7URVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ETWM2OD12Lki3Olch|ryP M3vSUnNCVkeHUh?=
TE-441-T NVX6epE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP3TWM2OD12LkmwOVM4KM7:TR?= NXfxdXo3W0GQR1XS
MOLT-16 NW\GNlV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjzXWxKSzVyPUSuPVUzPTNizszN NIT5[3hUSU6JRWK=
MCF7 NHfsO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwMUS1NVch|ryP MkHEV2FPT0WU
CAPAN-1 NFOycW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G3R2lEPTB;NT6yOVcxPyEQvF2= NIfnfYVUSU6JRWK=
PSN1 NXnCfVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwMkeyN|Uh|ryP NWjDN2ZLW0GQR1XS
NCI-H292 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuzXlVNUUN3ME21MlMxODR2IN88US=> MXzTRW5ITVJ?
CPC-N NXXJPIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3bGlEPTB;NT6zPVQyQSEQvF2= NY\lTI9iW0GQR1XS
DoTc2-4510 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofETWM2OD13LkS1N|cyKM7:TR?= MlvuV2FPT0WU
LB1047-RCC Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnGWpRNUUN3ME21MlU2QTN|IN88US=> MoX3V2FPT0WU
MHH-ES-1 NH30VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrsbWJ[UUN3ME21MlU6QTB5IN88US=> MleyV2FPT0WU
NMC-G1 M1TRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwN{CyNlch|ryP M2[4[XNCVkeHUh?=
SW1710 M2rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHrTWM2OD13Lke0O|UyKM7:TR?= M170WnNCVkeHUh?=
YAPC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrJcGZKSzVyPUWuO|YzODFizszN MUfTRW5ITVJ?
22RV1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXTJI1UUN3ME21MlgxODF7IN88US=> NFTNN2RUSU6JRWK=
COLO-679 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW1[Vh6UUN3ME21Mlg5QTR6IN88US=> NITGUGpUSU6JRWK=
TCCSUP M1vzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwOUOyOVkh|ryP MYDTRW5ITVJ?
C2BBe1 NV3McYdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwOUO5O{DPxE1? MXfTRW5ITVJ?
TE-15 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXkdldKSzVyPU[uNFY3ODVizszN MlTxV2FPT0WU
SCLC-21H M{jnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\3TWM2OD14LkGwPFQ{KM7:TR?= MmjlV2FPT0WU
EoL-1-cell NXLrT|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvqWodKSzVyPU[uNVY2PjNizszN NWLlbZZGW0GQR1XS
NKM-1 NFrvV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK0[mtKSzVyPU[uNVY4OSEQvF2= MY\TRW5ITVJ?
NCI-H1304 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IcoVKSzVyPU[uNlc1OjhizszN M3PBSXNCVkeHUh?=
NB6 M3;xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESwd4dKSzVyPU[uNlk3OjJizszN M3O3b3NCVkeHUh?=
NALM-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD14LkOzNlMh|ryP MXzTRW5ITVJ?
NCI-H522 NETM[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwM{OzNFYh|ryP M1OyVnNCVkeHUh?=
MV-4-11 NF\hWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfITWM2OD14LkO3NFc6KM7:TR?= NUW3OJF{W0GQR1XS
LB2241-RCC NX7mUZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwM{i2Olch|ryP NHHRe4JUSU6JRWK=
NCI-H1417 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZwNEC4OFch|ryP Mlu3V2FPT0WU
HT-1197 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULTOnFzUUN3ME22MlU4OTJ{IN88US=> MW\TRW5ITVJ?
P30-OHK MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7DV5BKSzVyPU[uOlI4PyEQvF2= NF[4VVZUSU6JRWK=
ALL-PO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u2WmlEPTB;Nj63NVkyPiEQvF2= NEDnVY9USU6JRWK=
OVCAR-4 NYq5VWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluyTWM2OD14Lke1OFA2KM7:TR?= NVy4VGFCW0GQR1XS
HCC2157 NV;zWos4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLsTWM2OD14Lke3OFc2KM7:TR?= NYW0bnAxW0GQR1XS
NCI-H838 M3H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPFTWM2OD14Lkm2OFkh|ryP NFHhXGtUSU6JRWK=
NCI-H1299 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TaZWlEPTB;Nj65O|A6KM7:TR?= NYPj[mx3W0GQR1XS
SW954 NXfHZmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PMUGlEPTB;Nz6yNFA3QCEQvF2= MmDkV2FPT0WU
NCI-H441 NH3RNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KxSGlEPTB;Nz6zOFA3PSEQvF2= MlTxV2FPT0WU
SK-MEL-2 NYLKSZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi2TYZnUUN3ME23MlQ5Ozd|IN88US=> Mnm4V2FPT0WU
KARPAS-45 NWLoTno3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwNkW5Nlkh|ryP M4jrTnNCVkeHUh?=
CAL-54 NHnWc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvtUmc{UUN3ME23MlgzQTd5IN88US=> M13pWnNCVkeHUh?=
KYSE-180 NUi0ZVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwOEi5OFEh|ryP NWHpXlJCW0GQR1XS
NCI-H187 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTdwOUW5OFch|ryP NHzSOotUSU6JRWK=
RT-112 NXz5[44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfHTWM2OD16LkC5Olc4KM7:TR?= NHHpNWVUSU6JRWK=
NCI-H1437 M16wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[2SGlEPTB;OD6wPVc6PSEQvF2= MmG3V2FPT0WU
SNU-449 NHzrfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PZc2lEPTB;OD6yPFI4OiEQvF2= NEe5XXBUSU6JRWK=
HCC1187 NXe0TXRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe2VWFpUUN3ME24MlI6OzlzIN88US=> M1:zeHNCVkeHUh?=
NCI-H2030 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33CcmlEPTB;OD6zO|cyPCEQvF2= MXrTRW5ITVJ?
HuO-3N1 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDpTWM2OD16LkO3PFQ1KM7:TR?= M2jITnNCVkeHUh?=
COLO-792 NUTPTI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pt[WlEPTB;OD60NVUzPyEQvF2= MUXTRW5ITVJ?
MIA-PaCa-2 M1K0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLITWM2OD16Lki1OVA5KM7:TR?= NXzVbGVxW0GQR1XS
SK-N-FI NXfmdFRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjoe|JKSzVyPUmuNFQzPSEQvF2= MUjTRW5ITVJ?
MMAC-SF Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvCenlKSzVyPUmuNFk4PTFizszN M{nvfHNCVkeHUh?=
NCI-H28 NGX4RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m3PGlEPTB;OT6xNFQ3QSEQvF2= NFn6[|VUSU6JRWK=
ETK-1 M4Tr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTlwMkm5O|Qh|ryP NHPDe2lUSU6JRWK=
NCI-H1993 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXtTWM2OD17LkS0NlYyKM7:TR?= Mmn0V2FPT0WU
no-11 NXHBfYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\tTWM2OD17LkS3NVIh|ryP MUDTRW5ITVJ?
ChaGo-K-1 NFi1fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTlwNUG1PFMh|ryP MmLHV2FPT0WU
NCCIT NHS4R5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\j[pN[UUN3ME25MlU{OTZ7IN88US=> NHzuNlBUSU6JRWK=
SAS NVvyVZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInLfpVKSzVyPUGwMlI1QCEQvF2= NVvFSI5qW0GQR1XS
A673 NV7kPZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkemNPUUN3ME2xNE4{PzB2IN88US=> NGm5c2dUSU6JRWK=
NCI-H1522 NWC1[WdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXIRW5LUUN3ME2xNE4{PzB5IN88US=> M{HGO3NCVkeHUh?=
NCI-H810 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[wb2lEPTB;MUCuN|kxPyEQvF2= MnXkV2FPT0WU
IST-MES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojRTWM2OD1zMD60OVY1KM7:TR?= MnjSV2FPT0WU
GR-ST MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXKUWpKSzVyPUGwMlUxOjRizszN M4LaTXNCVkeHUh?=
SUP-T1 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPZOmI4UUN3ME2xNE44OzF5IN88US=> MkXrV2FPT0WU
NB5 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHqXFI{UUN3ME2xNE46ODJ{IN88US=> NXvOb5V3W0GQR1XS
MZ1-PC NF3zU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK0TWM2OD1zMD65OVcyKM7:TR?= MYfTRW5ITVJ?
SK-CO-1 NGHmVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDWb2xKSzVyPUGwMlk6OzFizszN NGnnc|NUSU6JRWK=
Capan-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGxW2pKSzVyPUGxMlMyQThizszN M2jnNHNCVkeHUh?=
697 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzHVpRTUUN3ME2xNU43PzV5IN88US=> NWfHcXpmW0GQR1XS
REH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\MTWM2OD1zMT63OFUyKM7:TR?= M321UXNCVkeHUh?=
GI-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfIfGJKSzVyPUGxMlg3OTVizszN M1vVNHNCVkeHUh?=
BB65-RCC NW[1WXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sc2JKSzVyPUGyMlA6OTZizszN MXXTRW5ITVJ?
NCI-H1651 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPwOYlKSzVyPUGyMlI1PzhizszN NGLwXlRUSU6JRWK=
NCI-H1618 NUXyUFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3jXGp6UUN3ME2xNk4{QTd4IN88US=> MmPIV2FPT0WU
NCI-H2081 NHfzS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{Lk[xOFEh|ryP MkW2V2FPT0WU
GCIY NXTI[2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1SoE3UUN3ME2xNk44OjF|IN88US=> Mkn1V2FPT0WU
NY M3ixPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\4[XBKSzVyPUGzMlA3PDNizszN NWLUTo85W0GQR1XS
PANC-03-27 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF|LkC4NFch|ryP NEPlXI5USU6JRWK=
BHY MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF|LkKxNlEh|ryP NXr5OJoyW0GQR1XS
SK-OV-3 M4ridmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHHTWM2OD1zMz6zO|Y{KM7:TR?= MknUV2FPT0WU
5637 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33OcmlEPTB;MUOuO|c2QSEQvF2= M4fjSnNCVkeHUh?=
LC-1F NX\0RYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2LkCzOVYh|ryP NFr0RWlUSU6JRWK=
SNB75 NFrORmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD1zND6wN|g{KM7:TR?= M2DRdHNCVkeHUh?=
CHP-212 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XUO2lEPTB;MUSuNFQ3PCEQvF2= NVTUNIpWW0GQR1XS
HT-1376 NH61W2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H5[mlEPTB;MUSuNVEzPiEQvF2= MWnTRW5ITVJ?
MONO-MAC-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXOTZpKSzVyPUG0MlE2ODJizszN MV3TRW5ITVJ?
CA46 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqxNFlPUUN3ME2xOE4yQDJ5IN88US=> MkTkV2FPT0WU
SCC-15 NUHEXm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF2LkW1PFMh|ryP NXH2e5F2W0GQR1XS
ATN-1 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTrbXpKSzVyPUG0MlY3OjdizszN MX7TRW5ITVJ?
NCI-H2405 NUHRO3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF2LkixOVch|ryP NFrKc3VUSU6JRWK=
NCI-H716 M3;PV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\vcIhiUUN3ME2xOE45PDl|IN88US=> M3PXUHNCVkeHUh?=
SW620 M13uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnr[mE4UUN3ME2xOE46ODF2IN88US=> MoLXV2FPT0WU
NCI-H226 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF2LkmwPFUh|ryP NITLTm9USU6JRWK=
SW962 NV7sfIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzOTWM2OD1zND65OFMzKM7:TR?= M{KxXHNCVkeHUh?=
KYSE-150 M2K2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrIU3RKSzVyPUG0Mlk2PSEQvF2= MWfTRW5ITVJ?
OCUB-M MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\wWpVKSzVyPUG0Mlk5QDNizszN MUjTRW5ITVJ?
ES7 NHrqVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe2WHhUUUN3ME2xOU4xQTh2IN88US=> NVLMdYw6W0GQR1XS
SW1463 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP6TWM2OD1zNT60NlI{KM7:TR?= NV;HZ4FFW0GQR1XS
CAKI-1 NEHseoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37P[2lEPTB;MUWuOVM1PiEQvF2= NETGRlNUSU6JRWK=
MKN28 NV3BbFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XZc2lEPTB;MUWuOVQ4QSEQvF2= MYPTRW5ITVJ?
SW13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17pTWlEPTB;MUWuOlE5KM7:TR?= NYXROIlxW0GQR1XS
A3-KAW NH22dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LwSGlEPTB;MUWuPVY6PyEQvF2= NYX4U49JW0GQR1XS
LU-65 NYrhVog{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfieoRKSzVyPUG1Mlk4PjhizszN NE\YXo9USU6JRWK=
Calu-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PPb2lEPTB;MU[uNFM3QCEQvF2= MU\TRW5ITVJ?
ST486 NWfYW5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTKcHZFUUN3ME2xOk4xPDNzIN88US=> MWXTRW5ITVJ?
BB30-HNC MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL4TWM2OD1zNj6xNlQ3KM7:TR?= NYDMbWpVW0GQR1XS
EGI-1 NEC2eXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF4LkS0OkDPxE1? M{jjXXNCVkeHUh?=
SH-4 NXrXeYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDoTWM2OD1zNj60O|MyKM7:TR?= MULTRW5ITVJ?
MN-60 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PWU2lEPTB;MUeuNlI6PyEQvF2= NYnFN|VuW0GQR1XS
MPP-89 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHi[XYyUUN3ME2xO{4zPDV7IN88US=> M2jO[3NCVkeHUh?=
A2780 M{\4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi3WGVKSzVyPUG3MlQyOzlizszN MmfPV2FPT0WU
Daoy MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXuOGdKSzVyPUG3MlQ3QTVizszN NHS4VYxUSU6JRWK=
NCI-H2126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyTWM2OD1zNz60O|cyKM7:TR?= NXiyN41TW0GQR1XS
NCI-H1563 NFjwc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDEOXpZUUN3ME2xO{41QTF5IN88US=> MkHhV2FPT0WU
8-MG-BA NFS5N2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF5Lk[2OFgh|ryP Mn;4V2FPT0WU
786-0 M2q4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XScWlEPTB;MUeuPFM2OyEQvF2= M3jTWXNCVkeHUh?=
AM-38 NVLDXGJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHKTWM2OD1zNz65N|A3KM7:TR?= MXrTRW5ITVJ?
COLO-824 M16zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSxOHNKSzVyPUG4MlQ1OzZizszN M3XXXXNCVkeHUh?=
SK-MEL-30 M13OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD4dY5SUUN3ME2xPE42ODh{IN88US=> MWPTRW5ITVJ?
CESS MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn1UVVLUUN3ME2xPE44PjB7IN88US=> MWXTRW5ITVJ?
BL-70 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\5S3ZKSzVyPUG4MlgyPTZizszN NXTkXZZZW0GQR1XS
NCI-H2170 NUGxSFJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF6LkmxO|kh|ryP NEPJO4NUSU6JRWK=
HT-3 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnRNIlrUUN3ME2xPE46QDNizszN NWHwW5RNW0GQR1XS
BOKU NIjBSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIOWlEPTB;MUmuNFM5OSEQvF2= NH3l[VRUSU6JRWK=
HPAF-II NWTvV202T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhV3REUUN3ME2xPU4{ODF3IN88US=> MYTTRW5ITVJ?
KGN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCwNG5KSzVyPUG5MlQ4PjVizszN NV\aR5RyW0GQR1XS
MC-CAR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RWWFKSzVyPUG5MlY{OTNizszN NI[4eI5USU6JRWK=
BHT-101 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fNb2lEPTB;MUmuO|c4KM7:TR?= MXnTRW5ITVJ?
SW1783 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3RcHVYUUN3ME2xPU44QDB4IN88US=> MX7TRW5ITVJ?
KP-N-YN MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH6TWM2OD1{MD6wNlYzKM7:TR?= Mmq5V2FPT0WU
LU-165 NXXLWnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHZTWM2OD1{MD61OVcyKM7:TR?= M3L1OHNCVkeHUh?=
GOTO Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fPVGlEPTB;MkCuOlQ2OSEQvF2= M1jFN3NCVkeHUh?=
EFM-19 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2eyWGlEPTB;MkGuNFcyPiEQvF2= M3ny[nNCVkeHUh?=
CTV-1 M{PKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJzLkGwOVQh|ryP Mnv2V2FPT0WU
HEL NUfrZog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPqTWM2OD1{MT60NlE3KM7:TR?= NFLLTlJUSU6JRWK=
SNU-C2B M1vafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD1{MT60NlYh|ryP NXTZXIlQW0GQR1XS
ECC4 NXjubIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJzLkewO{DPxE1? M4m0e3NCVkeHUh?=
NEC8 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJzLkizOlgh|ryP Moe4V2FPT0WU
KMOE-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXoZ2hKSzVyPUKxMlg6OjFizszN NILOc4hUSU6JRWK=
NCI-H524 NEjrcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TDdmlEPTB;MkKuNFgxQCEQvF2= MYPTRW5ITVJ?
WSU-NHL NUHpVG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2[GlEPTB;MkKuNVU4PyEQvF2= NFzmO4VUSU6JRWK=
SF126 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ib4xbUUN3ME2yNk4zPDZ7IN88US=> NWexU2V1W0GQR1XS
HOP-92 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\IT4VnUUN3ME2yNk4{OTZ5IN88US=> MUfTRW5ITVJ?
CTB-1 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlryTWM2OD1{Mj60Olc4KM7:TR?= MkL5V2FPT0WU
KYSE-270 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHuNoRUUUN3ME2yNk46OzV5IN88US=> NX2xU2R3W0GQR1XS
SK-MEL-24 MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITnNpJKSzVyPUKzMlE5PyEQvF2= M3SzOXNCVkeHUh?=
Calu-3 M1jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme4TWM2OD1{Mz6yNVI5KM7:TR?= NEizO21USU6JRWK=
GAMG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ|LkKzOlch|ryP NIj2RZNUSU6JRWK=
SW1573 M373[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XhWGlEPTB;MkOuO|QyPSEQvF2= M4PqeXNCVkeHUh?=
MHH-NB-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP6XWZLUUN3ME2yOE4xOTl2IN88US=> MWLTRW5ITVJ?
TK10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ2LkWwNVMh|ryP MUfTRW5ITVJ?
LB373-MEL-D MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jlTmlEPTB;MkSuOlA3PCEQvF2= NXzadmltW0GQR1XS
KALS-1 M{ntTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXmUndKSzVyPUK0Mlc{OjdizszN MX\TRW5ITVJ?
HUTU-80 NF;TVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFXppKSzVyPUK1MlgxOzJizszN Mkf4V2FPT0WU
HuP-T3 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInpOW9KSzVyPUK2MlE3PzRizszN Mn36V2FPT0WU
OE19 NFTVeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ4LkKxOVMh|ryP NVnMbodLW0GQR1XS
J82 NXj3XlRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjYTWM2OD1{Nj6yOFcyKM7:TR?= MkHoV2FPT0WU
DU-4475 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zQSWlEPTB;Mk[uN|gyQSEQvF2= M3raVXNCVkeHUh?=
DMS-53 NVLNT|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ4LkWxN|gh|ryP MXPTRW5ITVJ?
COLO-741 M3[ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr2TWM2OD1{Nj64N|Q1KM7:TR?= MUjTRW5ITVJ?
SW48 NXjvRnJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\LdmhKSzVyPUK2Mlg5OiEQvF2= MmXlV2FPT0WU
IGR-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzVR|RKSzVyPUK2Mlk{OzRizszN MX\TRW5ITVJ?
639-V MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ5LkCyOFUh|ryP MkjIV2FPT0WU
LK-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrTTWM2OD1{Nz60NVQyKM7:TR?= NFzwUmVUSU6JRWK=
NCI-H2347 Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r6c2lEPTB;MkeuPVY6QSEQvF2= NVr3b|FiW0GQR1XS
NCI-H2228 NHvycGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG2bW1KSzVyPUK4MlA6ODVizszN NWHs[YpSW0GQR1XS
LS-123 NYXWfnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHZOJZDUUN3ME2yPE4yOjZ{IN88US=> NUHSe|ZtW0GQR1XS
U031 NXTyPYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ6LkK1NkDPxE1? NHfLb4dUSU6JRWK=
NCI-H1792 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3U4xKSzVyPUK4MlQ4OjFizszN NWrNTFNjW0GQR1XS
NCI-H2087 NFPLOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33kb2lEPTB;MkiuO|U2OiEQvF2= MYjTRW5ITVJ?
NCI-H2342 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ7LkWyNFgh|ryP Mn:zV2FPT0WU
SW626 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrUVolKSzVyPUK5Mlc2PiEQvF2= NUSxVlA2W0GQR1XS
LB2518-MEL NF;XbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3OmdKSzVyPUK5MlgyPSEQvF2= NXS0OnVDW0GQR1XS
RXF393 NHq4R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6zTnlpUUN3ME2zNE4xQTV{IN88US=> NUfJWYp5W0GQR1XS
LC4-1 NFOwb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNyLkOwPVIh|ryP NVXabZBjW0GQR1XS
NCI-H1694 NFfpfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PLOWlEPTB;M{CuOlYzPCEQvF2= MlT3V2FPT0WU
K5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\1TGpKSzVyPUOwMlk4ODJizszN Mn;1V2FPT0WU
HDLM-2 M{GwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1|MD65O|I2KM7:TR?= MYfTRW5ITVJ?
BCPAP MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37jbmlEPTB;M{GuPFM4QSEQvF2= MVTTRW5ITVJ?
BC-3 NUjRe2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLTTWM2OD1|Mj6xOFA{KM7:TR?= NEjUOXpUSU6JRWK=
LB996-RCC M1T2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\ScGN6UUN3ME2zNk4zOzV6IN88US=> MWLTRW5ITVJ?
NCI-H2009 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN{LkS5PFEh|ryP MX3TRW5ITVJ?
HTC-C3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPZSWhDUUN3ME2zN{44PTF7IN88US=> Ml7tV2FPT0WU
LAMA-84 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP3eXZKSzVyPUO0MlQ1ODdizszN MUjTRW5ITVJ?
CCRF-CEM NXzxO|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN2LkW3NVUh|ryP NUfCbnI2W0GQR1XS
AN3-CA NVHXZnhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqyd2RKSzVyPUO1MlA2PjhizszN MVrTRW5ITVJ?
NCI-H1734 NXjIN21TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\UWolPUUN3ME2zOU4zPTZzIN88US=> MnLaV2FPT0WU
Ca-Ski NUHUbG5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPpSFBKSzVyPUO1MlQyODFizszN M2X5THNCVkeHUh?=
U-266 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHJZ2RSUUN3ME2zOU43OTF2IN88US=> NH7LOpNUSU6JRWK=
SBC-5 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjiTWM2OD1|NT63O|gyKM7:TR?= NEj1XGxUSU6JRWK=
GT3TKB Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH21Z25KSzVyPUO3MlEyPSEQvF2= NIPvfmdUSU6JRWK=
MDA-MB-175-VII MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnDSVE{UUN3ME2zO{4zOjR6IN88US=> M{HWXHNCVkeHUh?=
PFSK-1 M3z0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PTcWlEPTB;M{euNlQ{PSEQvF2= M2D4bXNCVkeHUh?=
IMR-5 NEPVc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TDWWlEPTB;M{euNlQ5PyEQvF2= MoWzV2FPT0WU
Daudi MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN5LkO1PVch|ryP NHTTRY5USU6JRWK=
A498 NF[0NWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LlTmlEPTB;M{euO|IyQCEQvF2= NELRb3BUSU6JRWK=
SCC-4 NX[xNmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHxTWM2OD1|Nz63PFQ{KM7:TR?= MXTTRW5ITVJ?
COLO-680N NHjXN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq1dVBmUUN3ME2zPE4zQDh3IN88US=> MXvTRW5ITVJ?
SK-MES-1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3N2hKSzVyPUO4MlMzOTVizszN MWDTRW5ITVJ?
SR NYHYdoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjmT4NKSzVyPUO4MlU1QTVizszN MoD3V2FPT0WU
LNCaP-Clone-FGC M1nQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLU2lEPTB;M{iuOVY{PyEQvF2= MnzzV2FPT0WU
SK-HEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGxTWM2OD1|OD63PFIzKM7:TR?= M{PFcHNCVkeHUh?=
BPH-1 NX\qd|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H3VGlEPTB;M{iuPFMzQSEQvF2= M2n6XnNCVkeHUh?=
NCI-H1755 NFzyVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HDRWlEPTB;M{muOVgyPyEQvF2= MXXTRW5ITVJ?
LXF-289 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjrTWM2OD1|OT64NFg1KM7:TR?= MnvnV2FPT0WU
SW1088 NVPZTZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULwS|R7UUN3ME20NE4zOTB5IN88US=> NVW2V3lEW0GQR1XS
MOLT-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HmcGlEPTB;NECuNlkxOSEQvF2= NVvM[ZhpW0GQR1XS
AsPC-1 M{LUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQfHRkUUN3ME20NE41PTh|IN88US=> M3mwUnNCVkeHUh?=
HOP-62 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonXTWM2OD12MD62OVY5KM7:TR?= NHnFSotUSU6JRWK=
A172 M2W2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvyTWM2OD12MD64OVEyKM7:TR?= M4\JUnNCVkeHUh?=
SN12C NUK5dlRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHVTIZpUUN3ME20NE46Ozh3IN88US=> MkHQV2FPT0WU
MDA-MB-231 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRyLkm4PVgh|ryP NX[5dHBwW0GQR1XS
RPMI-2650 M1rybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRzLkG1PVMh|ryP MYLTRW5ITVJ?
KYSE-140 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHKSW5KSzVyPUSxMlgyOjNizszN NV:1bWlLW0GQR1XS
KINGS-1 M4CwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTR{LkS2PVch|ryP M{H0XXNCVkeHUh?=
HSC-3 NYPjWmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTR{Lk[2OlEh|ryP MYPTRW5ITVJ?
PC-14 NXrhWWxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nmc2lEPTB;NEOuNVg5OiEQvF2= M3PWN3NCVkeHUh?=
COR-L105 NF\LTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR|Lk[1NFIh|ryP MX\TRW5ITVJ?
BE-13 NWPtd|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rGVmlEPTB;NESuNlM4OSEQvF2= MWLTRW5ITVJ?
NCI-H661 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYVXJkUUN3ME20OE4zQTV6IN88US=> NIXhSWxUSU6JRWK=
IST-MEL1 NEfhPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyzUGpKSzVyPUS0MlM2QTlizszN NG\vfVlUSU6JRWK=
HCC1806 M1\S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLVTWM2OD12ND61PFc{KM7:TR?= MUnTRW5ITVJ?
COLO-800 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsNWlEPTB;NESuPFQ2OyEQvF2= NFTDeZpUSU6JRWK=
IST-SL2 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrkfm9wUUN3ME20OU4yOjR5IN88US=> NHTpXXlUSU6JRWK=
8305C NHXvZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7uTWM2OD12NT6zNFkh|ryP MYjTRW5ITVJ?
UACC-62 M3r6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m0[GlEPTB;NE[uNlg4PSEQvF2= NWCyUYxzW0GQR1XS
COR-L23 NVXlfIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPsboZwUUN3ME20O{4yQTlizszN NHzjUWNUSU6JRWK=
EFE-184 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR5LkO4PEDPxE1? NWf0cI5OW0GQR1XS
DMS-114 M4DrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDv[GJKSzVyPUS3MlQyPDlizszN Mn21V2FPT0WU
KYSE-520 NFTCZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TF[2lEPTB;NEiuOVMyPSEQvF2= MkW2V2FPT0WU
SNG-M NWPlbpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ne2lEPTB;NEmuOFM1KM7:TR?= MUXTRW5ITVJ?
A2058 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR7LkS4PFUh|ryP NIjafYZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib|Linsitinib ic50|Linsitinib price|Linsitinib cost|Linsitinib solubility dmso|Linsitinib purchase|Linsitinib manufacturer|Linsitinib research buy|Linsitinib order|Linsitinib mouse|Linsitinib chemical structure|Linsitinib mw|Linsitinib molecular weight|Linsitinib datasheet|Linsitinib supplier|Linsitinib in vitro|Linsitinib cell line|Linsitinib concentration|Linsitinib nmr|Linsitinib in vivo|Linsitinib clinical trial|Linsitinib inhibitor|Linsitinib Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID